Trial site
Inland Psychiatric Medical Group.
Chino, California 91710, United StatesNot linked to an institution yet
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 25 trials
- Status
- Recruiting7 trials
- Active, not recruiting3 trials
- Not yet recruiting1 trial
- Lead sponsor
- Bristol-Myers Squibb3 trials
- Novartis Pharmaceuticals2 trials
- ACADIA Pharmaceuticals Inc.1 trial
- Celgene1 trial
- Eli Lilly and Company1 trial
- and 3 more
Running trials
Not yet recruiting
A Study of Brenipatide in Participants With Major Depressive Disorder
NCT07928245· Phase 2· Eli Lilly and Company· Source
Contact: Nandita Puchakayala (principal investigator)
Recruiting
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
NCT07424404· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Nandita Puchakayala, Site 0058
Recruiting
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
NCT06947941· Phase 3· Bristol-Myers Squibb· Source
Contact: Nandita Puchakayala, Site 0031
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567· Phase 3· Bristol-Myers Squibb· Source
Contact: Nandita Puchakayala, Site 0058
Recruiting
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
NCT07226661· Phase 2· Supernus Pharmaceuticals, Inc.· Source
Contact: Gianpiera Ceresoli-Borroni, PhD
Recruiting
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667· Phase 2· ACADIA Pharmaceuticals Inc.· Source
Contact: Sandy Filosi
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913· Phase 3· Bristol-Myers Squibb· Source
Contact: Nandita Puchakayala, Site 0049
Active, not recruiting
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
NCT06052254· Phase 2· Teikoku Pharma USA, Inc.· Source
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984· Phase 2· Celgene· Source
Contact: Nandita Puchakayala, Site 0037
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error